Aerovate Therapeutics, Inc. (AVTE)
NASDAQ: AVTE · Real-Time Price · USD
2.790
+0.340 (13.88%)
At close: Nov 1, 2024, 4:00 PM
2.731
-0.059 (-2.11%)
After-hours: Nov 1, 2024, 7:02 PM EDT

Aerovate Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Selling, General & Admin
18.1917.1914.628.040.950.22
Research & Development
76.0364.2238.6214.997.943.11
Operating Expenses
94.2281.4153.2423.028.893.33
Operating Income
-94.22-81.41-53.24-23.02-8.89-3.33
Interest Expense
-----0.08-
Interest & Investment Income
6.345.951.830.07--
Other Non Operating Income (Expenses)
-0.01-0-0.08-0-00
EBT Excluding Unusual Items
-87.88-75.47-51.49-22.96-8.97-3.33
Other Unusual Items
-----0.64-
Pretax Income
-87.88-75.47-51.49-22.96-9.61-3.33
Income Tax Expense
0.060.060.030-0
Net Income
-87.94-75.52-51.51-22.96-9.61-3.33
Preferred Dividends & Other Adjustments
---0.020.15-
Net Income to Common
-87.94-75.52-51.51-22.99-9.76-3.33
Shares Outstanding (Basic)
2826241200
Shares Outstanding (Diluted)
2826241200
Shares Change (YoY)
13.63%7.60%99.06%4975.15%0.32%-
EPS (Basic)
-3.13-2.87-2.10-1.87-40.31-13.79
EPS (Diluted)
-3.13-2.87-2.10-1.87-40.31-13.79
Free Cash Flow
-74.61-56.92-39.32-27.58-7.86-2.78
Free Cash Flow Per Share
-2.65-2.16-1.61-2.24-32.44-11.52
EBITDA
-94.11-81.31-53.17-23.01-8.89-
D&A For EBITDA
0.110.10.070.020-
EBIT
-94.22-81.41-53.24-23.02-8.89-3.33
Source: S&P Capital IQ. Standard template. Financial Sources.